We are investigating potential claims for injuries suffered as a result of taking Vioxx® (rofecoxib). On September 30, 2004, pharmaceutical giant Merck & Company announced that it was withdrawing its arthritis drug Vioxx® from the market worldwide. The reason given was that "a clinical trial found an increased risk of heart attack and stroke." This was a big step for Merck because Vioxx was one of its most important drugs, with sales in 2003 of $2.5 billion.
Vioxx® Press Release (from Merck & Co.)
What Merck did not say was that the findings were nothing that should have surprised it since researchers have been warning about a connection between Vioxx and an increased risk of heart attack and stroke for years. Until last week, Merck brushed those studies aside, saying they were inconclusive because they lacked the rigor of a placebo-controlled clinical trial.
Merck has known for some time that Vioxx presented a problem. On September 17, 2001, the Food and Drug Administration sent Chief Executive Gilmartin an eight-page warning letter *, wherein the FDA said that Merck engaged "in a promotional campaign for Vioxx that minimizes the potentially serious cardiovascular findings that were observed" in a clinical trial comparing Vioxx® to naproxen, a less-expensive painkiller. "Your promotional campaign discounts the fact" that in the trial, "patients on Vioxx® were observed to have a four- to five-fold increase" in heart attacks, compared with patients on naproxen, the letter said.
* FDA letter to Merck (PDF Download)
Attorney John Evans (who manages this law firm's pharmaceutical practice) noted that the FDA approved the use of Vioxx® for infants over the weight of 22 pounds only two weeks prior to the worldwide withdrawal. The information Merck provided to the FDA in seeking this approval in the face of data showing a high correlation between Vioxx® and heart attack/stroke may be difficult for Merck to explain.
If you believe that you or a relative were injured by taking Vioxx® please use the form below to contact our law firm.
Adobe Reader is required to view the PDF document above.
Get Adobe Reader
Copyright © 1999-2008 Specter Specter Evans & Manogue, P.C.
Terms of Use
Dr. Graham Speaks Out on Vioxx® Verdict
Attorneys for Alleged Victims of Vioxx® Welcome Ruling
Researchers Wanted Safer, Reformulated Vioxx®
Vioxx® Linked to Heart Attacks
FDA Called Journal to Block Vioxx® Article
Vioxx® Hearing Summary from Senate Finance Committee
FDA, Merck and Vioxx: Putting Patient Safety First?
Senate Hearings began November 18, 2004, at 10:00 a.m. in 216 Hart Senate Office Building into Merck and the FDA's handling of the Vioxx® recall. Click here for up to the minute information on the U.S. Senate Finance Committee website.
Vioxx® Recall Featured on 60 Minutes
Vioxx® Should Have Been Withdrawn
Linking COX-2 Inhibitors and Cardiovascular Event Risk
Earlier Vioxx® Warnings Dismissed by Merck
Merck Posts 21 percent Decline in 4Q Profits on Vioxx® Withdrawal
Merck's Debt Ratings Fall on Vioxx® Concerns
Formal Investigation of Vioxx® Recall
